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LABORATORY AND CLINICAL STUDIES OF A NEW ANTIBIOTIC, CEPHALORIDINE,
IN THE TREATMENT OF GRAM-POSITIVE INFECTIONSt
The history of the development of the cephalorsporins from a strain of the
mold Cephalorsporium acrentonium is reviewed elsewhere.' Synthetic
manipulation of the cephalosporin nucleus (7-amino-cephalosporanic acid)
has resulted in two useful antimicrobial agents: cephalothin, 7-(thiophene-
2-acetamido)-cephalosporanic acid, and cephaloridine, 7-[(2-thienyl)aceta-
mido]-3-(1-pyridylmethyl)-3-cephem-4-carboxylic acidbetaine.2" Cephalori-
dine has essentially the same antibacterial spectrum as cephalothin in vitro
and is thought to be bactericidal for Gram-positive bacteria.2 The pharmaco-
logic properties of the two drugs are similar. Cephaloridine is a poten-
tially useful antimicrobial agent because of its high biological activity,
sustained serum levels following a single intramuscular injection' and low
toxicity in animals' and man.24 The present report describes the clinical
efficacy and toxicity of relatively small daily doses of cephaloridine in the
treatment of Gram-positive infections, and in zitro studies comparing the
single high-concentration disc method with the tube-dilution method in
determining the antimicrobial sensitivities of 138 Gram-positive organisms
isolated from patients with infections.
MATERIALS AND METHODS
Clin.ical studies
Twenty-four male patients admitted to the acute medical wards of the West Haven
Veterans Administration Hospital with clinically serious Gram-positive infections-
and who consented to the study-received cephaloridine therapy. Patients were ad-
mitted to the study when the clinical history and careful examination of a gram stain
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of purulent material suggested Gram-positive pyogenic infection. In addition, appro-
priate pretreatment cultures were inoculated directly onto blood agar, phenol ethanol,
and MacConkey's media. Venous blood cultures were obtained on all patients with
fever in excess of 100° F. Pneumococci were identified by the inhibitory effect of
a filter paper disc impregnated with five micrograms of ethyl hydrocuprein hydro-
chloride.' Beta hemolytic streptococci were grouped on the basis of inhibition by
a disc impregnated with 0.02 units of bacitracin.8 Coagulase-positive staphylococci
were considered to be Staphylococcus aureus.
Cephaloridine was supplied in ampules containing one gram of white powder,*
which was dissolved in 2 to 4 milliliters of sterile normal saline prior to use. All
patients were treated with cephaloridine by the intramuscular route since absorption
after oral administration is poor.' Dose and duration of therapy was determined by the
type of infection, antibiotic sensitivity pattern of the infecting agent and the patient's
clinical response. The most frequent dosage schedule consisted of 250 milligrams,
12 hourly for 10 days, but ranged from 0.5 grams to 4 grams per day for 5 to 42 days.
The drug was used preferentially in patients with a history of penicillin hyper-
sensitivity. Patients were excluded from the study if they received concomitant therapy
with other antibiotics. Toxic effects of the drug were assessed by white blood cell
count, differential cell count, hematocrit, total and direct bilirubin, serum glutamic
oxaloacetic acid transaminase, thymol turbidity, cephalin flocculation, blood urea
nitrogen, and urinalysis values obtained prior to, during, and after therapy. Erythro-
cyte glucose-6-phosphate dehydrogenase activity was determined on some patients by
the brilliant cresyl-blue dye test.'17
Laboratory studies
One hundred thirty-eight strains of Gram-positive bacteria isolated from patients
with clinical infections hospitalized at the West Haven Veterans Administration
Hospital were studied. These included 38 strains of Staphylococcus aureus, 28 strains
of Staphylococcus albus, 18 strains of Diplococcus pneumoniae, 17 strains of Beta
hemolytic streptococci, 21 strains of Streptococcus viridaAns, and 16 strains of Strepto-
coccus faecalis (enterococci). Organisms were collected from the Clinical Bacteriology
Laboratory, subcultured, and re-identified according to the scheme of Schaub, Foley,
Scott, and Bailey8 in our Research Bacteriology Laboratory before antibiotic sensi-
tivity tests were performed.
All organisms were tested with cephaloridine by both tube-dilution and single
antibiotic disc methods. In addition, organisms were tested with four other antibiotics
by the single disc method. Discs (Difco) contained the following concentrations of
antibiotics: cephalothin, 30 micrograms; penicillin G, 2 and 10 units; methicillin,
5 micrograms; and nafcillin, 1 microgram. A modification of the single-disc method of
Kirby, Yoshihara, Sundstedt, and Warren9 and Turck, Lindemeyer, and Petersdorf'0
was used in the present study. The total diameter of the zone of inhibition, including
the diameter of the disc (6 millimeters) was measured after overnight incubation of
the plates at 370 C. Tube dilution sensitivities were performed as follows: 1 to 2
colonies of a pure culture of each isolate were transferred from stock media into
10 milliliters of tryptocase soy broth and incubated for 6 to 8 hours at 370 C. On
occasion, slowly growing organisms were incubated overnight. The broth cultures
* Supplied by Dr. R. S. Griffith of Eli Lilly and Company, Indianapolis, Indiana.
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were then serially diluted in broth to a final dilution of 10-' so that 1 milliliter of
broth contained approximately 100,000 organisms. Serial pour plate dilutions were
performed on the final broth inoculum to verify the exact number of organisms
present. A one-milliliter sample containing approximately 100,000 bacteria was then
added to one milliliter of antibiotic in final concentration of 0.05, 0.1, 0.2, 0.39, 0.78,
1.56, 3.13, 6.25, 12.5, 25, and 50 micrograms per milliliter. The tube with the lowest
concentration of antibiotic showing complete macroscopic inhibition of growth after
24 hours incubation at 370 C. was considered as the bacteriostatic end point, minimum
inhibitory concentration (MIC). In addition, all tubes showing complete macroscopic
inhibition of growth after 24 hours of incubation were then subcultured by the quanti-
tative pour plate dilution technique" to determine whether bacteria were present. The
tube with the lowest concentration of antibiotic that was sterile when subcultured was
interpreted as the bactericidal end point, minimum bactericidal concentration (MBC).
Organisms were considered to be sensitive if their growth was inhibited by 12.5 micro-
grams per milliliter or less of cephaloridine since this concentration represents the
average peak serum level attained after a single 500-milligram intramuscular dose of
this antibiotic.'
RESULTS
Clinical studies
Of the twenty-four patients treated with cephaloridine, eighteen had
clinical evidence of bacterial pneumonia. Sixteen of these patients had an
underlying illness complicating their pneumonia: alcoholism in 6, chronic
pulmonary disease in 3, congestive heart failure in 4, diabetes mellitus and
lymphoma in 1 each and 1 patient had cancer and chronic pulmonary
disease. All patients were seriously ill. Pneumococci were seen on gram
stain of sputum in 17 and were isolated from sputum cultures in 12 and
from blood cultures in 3 patients. One patient had staphylococcal pneu-
monia. Sixteen patients had roentgenographic evidence of pulmonary
infiltration.
The first nine of these 18 patients with pneumonia received 250 milli-
grams of cephaloridine every 12 hours and were treated for 5 to 12 days,
receiving from 2.25 to 5.75 grams during therapy. Eight of these nine
patients responded satisfactorily and were cured of the infection. One
patient with Hodgkin's disease was admitted to hospital with a month
history of cough, fever, pleuritic chest pain and purulent sputum. Pneumo-
cocci were cultured from sputum prior to therapy but could not be recovered
from sputum cultured after two days of cephaloridine treatment. Never-
theless, fever and pulmonary infiltration remained unchanged despite eight
days of antibiotic therapy. Subsequent nitrogen mustard therapy produced
a dramatic lysis of fever. The pulmonary infiltrate remained unchanged
radiographically for several months at which time the patient died of
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Hodgkin's disease. A chronic pneumonia was demonstrated at post mortem
examination. Although the clinical response to this dose of cephaloridine
appeared satisfactory in the eight patients who recovered, they became
afebrile slowly (mean duration of fever 3.6 days).
The next nine patients with bacterial pneumonia were subsequently
treated with one gram of cephaloridine administered initially, followed by
250 milligrams at 12-hour intervals for 6 to 10 days, receiving from 3.25 to
5.25 grams of cephaloridine during this period. Eight patients in this
group responded satisfactorily to treatment with more rapid lysis of fever
(mean duration of fever 1.7 days) as compared with patients receiving an
initial dose of 250 milligrams of cephaloridine. One patient with cancer and
chronic pulmonary disease died on the sixth day of cephaloridine therapy.
Of the remaining six patients treated with cephaloridine five had soft
tissue infections and one had a brain abscess. Organisms were recovered
from these patients by aspiration of advancing margins of cellulitis or small
open lesions of the infected area. Four patients were treated for cellulitis
due to mixed infections caused by Staphylococcus aureus and Group A beta
hemnolytic Streptococci. Staphylococcus aureus and Escherichia coli were
cultured from a brain abscess which was the most severe infection treated
in this group. This patient was febrile, comatose and hemiparetic at the
initiation of therapy. Cephaloridine, 1 gram every 6 hours, was administered
for two weeks combined with early incision and drainage, followed by 0.5
gram of cephaloridine every 6 hours for an additional four weeks, which
resulted in prompt improvement and complete recovery. One patient with
long-standing agranulocytosis of uncertain etiology responded clinically to
cephaloridine and surgical drainage of a palmar abscess from which Staphy-
lococcus albus and Aerobacter species were cultured although the gram-
negative rod was not sensitive in vitro to cephaloridine.
Laboratory abnormalities potentially attributable to cephaloridine therapy
were observed in five patients. Two of six Negro patients developed anemias
during treatment and both patients were found to have glucose-6-phosphate
dehydrogenase deficient erythrocytes.* Hematocrit determinations returned
to normal values following therapy.
A past history of penicillin hypersensitivity was obtained from 7 of the
24 patients studied and one developed asymptomatic eosinophilia during
therapy. No allergic manifestations were observed in other patients studied.
Two patients developed transient elevations of the serum glutamic-
oxaloacetic-transaminase during therapy. One patient had received whole
*Erythrocyte glucose-6-phosphate dehydrogenase determinations were kindly per-
formed by Dr. P. E. Perillie.
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blood transfusions 42 days previously. An additional patient demonstrated
a progressive rise in serum glutamic-oxaloacetic transaminase values to 88
units which rapidly returned to normal values when cephaloridine was dis-
continued. Normal values of other tests of liver function were observed in
both patients during and after therapy.
Eighteen of the 24 patients had normal renal function prior to, during,
and after cephaloridine treatment. Six patients had elevated blood urea
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nitrogen values at the initiation of cephaloridine therapy. Blood urea nitro-
gen values fell to normal during treatment in four patients and remained
elevated but did not increase significantly during therapy in two patients.
No abnormalities in white blood cell count, differential cell count, total
and direct bilirubin, thymol turbidity, cephalin flocculation and urinalysis
values were observed during therapy.
The intramuscular administration of cephaloridine was well tolerated by
all patients and no patient complained of pain on injection.
Laboratory studies
Tube-dilution sensitivity of Gramt-positive isolates to cephaloridine. The
bacteriostatic and bactericidal activity of cephaloridine tested against 105
bacterial cells of Staphylococcus aureus, Staphylococcus albus, Diplococcus
pneumoniae, Streptococcus pyogenes, Streptococcus viridans, and Strepto-
coccus faecalis are summarized in Table 1 and Figure 1. This antibiotic in-
hibited 100 per cent of S. aureus, 100 per cent of penicillin-sensitive S. albus,
85 per cent of penicillin-resistant S. albus, 100 per cent of D. pneumoniae,
95 per cent of S. viridans, 76 per cent of S. pyogenes, and only 37 per cent
of S. faecalis. Cephaloridine was also found to be bactericidal for the major-
ity of susceptible strains and there was, in general, a close correlation
between inhibition (MIC) and killing (MBC) of most Gram-positive
bacteria. The cumulative per cent of these strains susceptible to increasing
concentrations of cephaloridine is shown in Figure 1.
Comparison of single disc and tube dilution sensitivities. The zone diam-
eter of inhibition of Gram-positive bacteria tested with 30 micrograms of
cephaloridine is illustrated in Figure 2. A zone size of 6 millimeters indicates
no inhibition since the antibiotic disc has a diameter of 6 millimeters and
this diameter is included in the final reading. The zone of inhibtion for each
strain studied is plotted against the minimum concentration (MIC) of
cephaloridine necessary to inhibit the growth of that strain as determined
by tube-dilution sensitivities. Figure 2 illustrates the close correlation be-
tween disc and tube-dilution sensitivities of cephaloridine against S. aureus,
S. albus, D. pneunzoniae, S. ziridans, and Beta hemolytic streptococci. Most
discrepancies between disc and tube-dilution sensitivities were observed
with strains of S. faecalis. With the exception of enterococci, Gram-positive
bacteria with zones of inhibition greater than 14 millimeters had minimunm
inhibitory concentrations well within the expected serum level of cephalo-
ridine following a single intramuscular injection of 250 or 500 milligrams.3
In contrast, five strains of S. faecalis with zones of 14 or more millimeters
of inhibition had minimum inhibitory concentrations of 25 micrograms or
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more per milliliter of cephaloridine and one strain with a zone of inhibition
of only 12 millimeters had a minimum inhibitory concentration of 0.02
micrograms per milliliter. However, the disc sensitivity method was only
misleading when enterococci were studied.
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Comnparison by disc sensitivity of cephaloridine wtih other antibiotics.
Figure 3 illustrates the comparative disc sensitivity of 138 strains of Gram-
positive bacteria when tested against cephaloridine, cephalothin, penicillin
G, methicillin, and nafcillin. The per cent of strains inhibited by a 30-micro-
gram cephaloridine disc compared favorably with those inhibited by a 30
microgram cephalothin disc. Although 12 strains of S. faecalis were sensi-
tive to cephaloridine by the disc method, only six of these were also
sensitive by the tube-dilution method. One strain of a Group A beta
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hemolytic streptococcus was also sensitive to cephaloridine by the disc
method but resistant by tube-dilution sensitivity.
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DISCUSSION
The results of this study suggest that cephaloridine is an effective anti-
microbial agent in the therapy of pulmonary and soft tissue infections due
to pneumococci, group A beta hemolytic streptococci and staphylococci.
Twenty-two patients treated with cephaloridine were cured of their infec-
17YALE JOURNAL OF BIOLOGY AND MEDICINE
tion. One patient, although bacteriologically "cured," was considered a
treatment failure when fever and pulmonary infiltration persisted. How-
ever, these latter findings were probably due to Hodgkin's disease since
fever promptly disappeared with nitrogen mustard therapy. Athough small
doses of cephaloridine (250 milligrams every 12 hours) were effective in
the treatment of pneumococcal pneumonia, in this study an initial dose of
one gram followed by 250 milligrams every 12 hours resulted in more
rapid clinical improvement.
These excellent therapeutic results are in contrast with previous studies2"
in which cephaloridine was used to treat predominately Gram-negative
infections. Murdoch and colleagues4 observed treatment failures in 46 per
cent of 43 patients studied and Stewart and Holt2 reported that 25 per cent
of patients failed to respond to cephaloridine therapy. Urinary tract abnor-
malities and the presence of foreign bodies were thought to be responsible
for the poor results observed. However, the minimal inhibitory concen-
tration of cephaloridine for most susceptible Gram-negative bacteria is one
hundred to one thousand times greater than for Gram-positive cocci.'
Stewart' also noted less striking cellular morphologic abnormalities in
Gram-negative rods exposed to cephaloridine than at equivalent concen-
trations of ampicillin or penicillin G. These observations may also account
for the less impressive results observed in the treatment of Gram-negative
infections.
Toxicity of new therapeutic agents is difficult to assess during prelim-
inary clinical studies since patients are often quite ill with multiple system
disease and receive many pharmacologically active agents. Adverse reactions
should not be considered "documented" in the absence of confirmatory
laboratory tests or rechallenge with the suspected agent.'
Five patients treated with cephaloridine developed probable adverse
reactions that might be attributed to the drug. None of these reactions
was severe or life-threatening. The elevated serum glutamic-oxalacetic-
transaminase values noted in two patients were minimal and were the only
abnormalities of liver function observed. A previous blood transfusion in one
patient complicates interpretation since elevated transaminase values may
be the only indication of serum hepatitis.'l Slight elevations of serum trans-
aminase values have been occasionally observed in patients treated with
other antibiotics.' The significance of these observations has not been clearly
defined. Eosinophilia was the only allergic reaction observed and occurred
in one patient with a past history of penicillin hypersensitivity.
The anemia that developed in two patients with glucose-6-phosphate
dehydrogenase-deficient erythrocytes appeared to be drug related although
18
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pneumococcal infection may have been responsible, at least in part, for the
fall in hematocrit values. Anemia has not been reported in other patients
treated with cephaloridine."' It is unlikely that patients with this enzyme
deficiency were studied previously although reports from Great Britain do
not identify the racial background of cephaloridine-treated patients.2'
Further clinical investigation is necessary to define more clearly this
apparent association and other potential adverse reactions to cephaloridine.
Progressive nitrogen retention, which has recently been observed in some
patients with initially normal or reduced renal function when large daily
doses of cephaloridine have been administered,'5 did not occur with small
daily doses of cephaloridine even though some patients had reduced renal
function before therapy.
Cephaloridine and cephalothin are both clinically effective in the treatment
of infections due to the pneumococcus, group A beta hemolytic strepto-
coccus and penicillinase and nonpenicillinase-producing staphylococcus and
can probably be used with relative safety in penicillin-sensitive individuals.3
However, an anaphylactoid reaction to cephalothin has been described in a
penicillin-sensitive patient.16
When compared with cephalothin, cephaloridine has the distinct advan-
tages of greater potency against bacterial infections caused by Gram-
positive cocci, less frequent injections, less and frequently absent pain at the
injection site, greater solubility, absence of protein binding, and prolonged
antibacterial serum levels.2"
Finally, the results of the laboratory data observed in the present study
indicate that, with the exception of some strains of enterococci, the single
high-concentration disc method correlates closely with the tube-dilution
method and is reliable in determining the antimicrobial sensitivity or re-
sistance of strains of staphylococci, pneumococci, and streptococci to
cephaloridine.
SUMMARY
The new semisynthetic antibiotic, cephaloridine, was effective in the
treatment of twenty-two of twenty-four pulmonary and soft tissue bacterial
infections due to staphylococci, pneumococci, and streptococci. Although
sixteen of eighteen patients with pneumonia responded well to therapy,
those treated with a higher initial dose of cephaloridine seemed to improve
and become afebrile more rapidly. Anemia developed during therapy in
two patients with glucose-6-phosphate dehydrogenase-deficient erythrocytes
and was the most significant adverse effect observed. Progressive nitrogen
retention was not observed during or after therapy in six patients with
elevated blood urea nitrogen values prior to cephaloridine treatment.
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In sitro sensitivity studies of 138 Gram-positive organisms indicated
that, with the exception of enterococci, the single high-concentration disc
method compared favorably with the tube-dilution method and was reliable
in determining the antimicrobial sensitivity of strains of staphylococci,
pneumococci, and streptococci to cephaloridine.
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